Eesti - eesti - Ravimiamet

beaphar b.v. - dimpülaat - ravimkaelarihm - 150mg 1g 65cm 1tk; 150mg 1g 35cm 1tk

Eesti - eesti - Ravimiamet

virbac - dimpülaat - ravimkaelarihm - 15g 100g 16.7g 1tk; 15g 100g 38.2g 1tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 20mg 100tk; 20mg 30tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 30mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 40mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 60mg 30tk; 60mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 50mg 30tk; 50mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 70mg 100tk; 70mg 30tk

Eesti - eesti - Ravimiamet

ferring gmbh - desmopressiin - süstelahus - 15mcg 1ml 2ml 5tk; 15mcg 1ml 1ml 5tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.